HLTHQ Cue Health Inc. (PNK) at $0.000001 on 22 Jan 2026: Chapter 7 fallout remains
HLTHQ stock opened market hours on 22 Jan 2026 at $0.000001 on the PNK exchange after extended declines tied to the company’s Chapter 7 liquidation filing. The share price shows a -99.00% one‑day change versus the previous close of $0.000100, with volume 12,888 shares traded. Investors view the move as a continuation of post‑bankruptcy selling and extreme illiquidity in the United States OTC market. We assess what the price action means for holders, valuation metrics and near‑term trading risks.
Why HLTHQ stock is a top loser today
HLTHQ stock is down to $0.000001 after Cue Health Inc. filed for Chapter 7 liquidation in May 2024. The bankruptcy process and halted operations reduced expected cash flows and crushed market confidence, pushing market cap to $159.00. Low liquidity and a one‑day change of -99.00% make the name a top loser in market hours on 22 Jan 2026.
Price, volume and trading context for HLTHQ stock
Intraday range for HLTHQ was $0.000001 to $0.000100 with 12,888 shares traded versus an average volume of 181,687. Shares outstanding stand at 159,091,810, so on‑exchange turnover is tiny relative to float. The price average 50‑day is $0.000003 and 200‑day is $0.000002, reflecting persistent near‑zero trading levels.
Financials and valuation metrics driving HLTHQ stock moves
Cue Health reports EPS -2.13 and operates in Healthcare — Medical Devices. Key ratios show a current ratio 2.54 and cash per share $0.53, but enterprise value is distorted at -32,949,841.00. Price‑to‑sales and price‑to‑book metrics are essentially zero due to the tiny share price, removing meaningful market valuation signals.
Meyka Grade and technical snapshot for HLTHQ stock
Meyka AI rates HLTHQ with a score out of 100: 57.89 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show extreme weakness: RSI 0.00, ADX 100.00 and near‑zero liquidity, which supports the C+ grade as a conditional hold for very risk‑tolerant traders.
Risks and what could move HLTHQ stock
Primary risks are Chapter 7 outcomes, continued delisting or administrative removal from platforms, and bilateral creditor settlements that erase common equity. Potential catalysts that could change the picture are asset buyouts, litigation recoveries that create a distribution, or regulated reorganization news. Absent those, price will likely remain at near‑zero levels.
Short‑term trade setups and sector perspective on HLTHQ stock
For active traders, the technical environment suggests only speculative microcap plays with tight risk controls. The Healthcare — Medical Devices sector shows broader recovery, but HLTHQ’s operational and legal state isolates it from sector gains. We recommend small position sizes only for those who accept near‑total capital loss risk.
Final Thoughts
Key takeaways on HLTHQ stock: the market price at $0.000001 on 22 Jan 2026 reflects Chapter 7 liquidation and effectively zero trading liquidity. Financial metrics show EPS -2.13 and cash per share $0.53, but enterprise value and valuation ratios are distorted by the micro‑price. Meyka AI’s forecast model projects a yearly price of $0.45, implying an extreme theoretical upside of about 45,213,900.00% from the current price, but this scenario assumes a full recovery and successful asset monetization. Short‑term realistic technical levels to monitor are $0.000100 (near prior intraday highs) and a downside floor at $0.000001 given current bids. There is no consensus price target from sell‑side analysts. Investors should treat HLTHQ as a highly speculative, binary outcome equity; legal developments around the liquidation will determine any meaningful value. For the latest filings and ratio updates see StockAnalysis HLTHQ ratios and market coverage at Markets Insider. Meyka AI provides this as an AI‑powered market analysis platform insight and not financial advice. Forecasts are model‑based projections and not guarantees.
FAQs
Why did HLTHQ stock fall to $0.000001?
HLTHQ stock plunged after Cue Health filed for Chapter 7 liquidation and market confidence evaporated. Bankruptcy outcomes and near‑zero liquidity forced steep price declines and heavy selling pressure in the OTC market.
What is Meyka AI’s view on HLTHQ stock recovery prospects?
Meyka AI’s forecast model projects a yearly price of $0.45 as a best‑case recovery scenario, but that assumes asset monetization and creditor payouts. This is model‑based and not a guarantee.
Is HLTHQ stock tradable on the PNK exchange now?
Yes, HLTHQ is actively trading on PNK in the United States, but volume is thin and bid/ask spreads are extreme. Traders should use strict risk limits and expect potential administrative trading halts.
What financial metrics matter most for HLTHQ stock now?
For HLTHQ, cash per share ($0.53), shares outstanding (159,091,810), cash runway and bankruptcy settlement signals are the most relevant metrics for any possible distribution to equity holders.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
